Southampton helps trial new ‘universal vaccine’ technology
Date:
The first human clinical trial of a universal Sarbeco coronavirus vaccine has shown that the vaccine is safe and has no significant side-effects.
The technology was developed by the University of Cambridge and spin-out DIOSynVax (DVX) Ltd. It was jointly trialled by Cambridge, and by the University of Southampton and the NIHR Southampton Clinical Research Facility .
Read the full article here.
